Home / Commonwealth Partnerships for Antimicrobial Stewardship Scheme
Hero image

Commonwealth Partnerships for Antimicrobial Stewardship Scheme

Working together to improve the detection and monitoring of resistant infections at the hospital level, taking measures to reduce infection and ensuring antibiotics' effective use.

Blue leaf
Blue leaf

Call for applications is now open!

 

We are delighted to announce the call for applications for the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme!

Funded by the UK Department for Health and Social Care’s Fleming Fund and managed by THET and the Commonwealth Pharmacists’ Association, CwPAMS will see up to 12 Commonwealth partnerships receive funding to tackle the growing challenge of antimicrobial resistance in Ghana, Tanzania, Uganda and Zambia.

A total of £600,000 is available to partnerships, with projects expected to run from February 2019 to April 2020.

 

Key information:

  • Application deadline is midnight on the 4th January 2019 and completed applications should be sent to ams@thet.org
  • Grants are restricted to projects in Ghana, Tanzania, Uganda and Zambia
  • Grants are available for projects focussed on:
    •  Antimicrobial stewardship, including surveillance (AMS) – requirement;
    •  Antimicrobial pharmacy expertise and capacity – requirement;
    • Infection Prevention Control (IPC)
  • Grants are available for a period of 15 months and should begin from 1st February 2019.
    • All activity must be completed by 30th April 2020 with final reports due by 15th May 2020.
    • There are two tiers of funding available:
      •  Category A. £10,000 – £30,000: for new partnerships
      •  Category B. £30,000 – £75,000: for established  partnerships

 

Hero image

 

The Fleming Fund

The Fleming Fund is a UK aid programme, helping low- and middle-income countries tackle antimicrobial resistance (AMR). Its aim is to improve the surveillance of AMR and generate relevant data that is shared nationally and globally.

The Scheme

Antimicrobial resistance (AMR) is a growing threat and occurs when microorganisms survive exposure to a medicine, such as antibiotics, antimalarials or antivirals, that would normally kill them. Our misuse and overuse of antibiotics are largely accelerating this global problem.

The new Commonwealth Partnerships for Antimicrobial Stewardship scheme, funded by the UK Department for Health and Social Care’s Fleming Fund, will see up to 12 Commonwealth partnerships receive funding. Multidisciplinary teams will travel to Ghana, Tanzania, Uganda and Zambia to work in partnership with local health workers to tackle the growing challenge of AMR.

A total of £600,000 is available to partnerships as part of the Fleming Fund, a wider commitment by the UK Government to spend up to £265 million of UK aid to support low and middle-income countries to enhance their surveillance of AMR by 2021.

Projects are expected to run from March 2019 to April 2020. Undertaking regular short-term visits, the partnerships will leverage the expertise of UK health institutions and technical experts to strengthen the capacity of the national health workforce and institutions to address predefined AMR challenges.

The Grants

Grant size and duration:
  • Grant duration is 15 months, from February 2019 – April 2020
  • Funding of £30,000 – £75,000 is available for established health partnerships.
  • Funding of £10,000 – £30,000 is available for new health partnerships.
Eligibility criteria:
  • A health partnership is a long-term arrangement between a health institution in the UK with a similar, counterpart institution in a low or middle-income country. The lead institutions must be formally recognised as a health education institution, regulatory organisation or NHS (if the UK) or public/not-for-profit (if overseas) hospital. This can include Professional Associations and whilst an academic institution or professional association can act as the official lead for a grant, there must be clear joint leadership from an NHS hospital.
  • A key component of any project is the use of UK NHS staff who will volunteer their time to support and train low or middle-income country staff.
  • Staff salary contributions for project management and monitoring & evaluation in the UK or overseas are allowed.
Programme indicators:
  • Institutions and workforce demonstrate improved knowledge and practice related to IPC, AMS and prescribing practice
  • Evidence on effective AMR interventions and tools to support this are being used by national partners.
  • NHS staff demonstrate improved leadership skills and a better understanding of the global context of AMR in their work.

 

Despite great advances in modern medicine we are facing a post-antibiotic apocalypse if we do not act now.

Professor Dame Sally Davies - Chief Medical Officer, England

Hero image

Antimicrobial Resistance causes

700,000

deaths globally

Why Antimicrobial Resistance?

AMR poses a catastrophic threat to us all and yet until recently it has remained a neglected area of global health.

A number of factors can increase the spread of resistant microorganisms. For example, antimicrobial drugs are often used unnecessarily, which increases the risk that microorganisms can become resistant, survive and multiply. In 2016, 490,000 people developed multi-drug resistant TB, and drug resistance is starting to complicate the fight against HIV and malaria as well.

The independent Review on antimicrobial resistance estimated that,

at least 700,000 deaths each year globally are attributable to drug resistance to infections including bacterial infections, malaria and HIV/AIDS.

Unless action is taken, it is thought the burden of deaths from AMR could balloon to 10 million lives each year by 2050 and cost the global economy up to $100 trillion US Dollars.

It is estimated that 5000 deaths are already caused every year in the UK alone because antibiotics no longer work for some infections.

Rising drug resistance is a global hazard and if we do not tackle it, every day procedures such as caesarean sections, cancer therapy, and hip replacements will become extremely dangerous.

Antimicrobial resistance poses a catastrophic threat to us all and yet until recently it has remained a neglected area of global health. At THET we believe that working in partnerships is the best way to strengthen health systems both at home and overseas.

Ben Simms - Chief Executive Officer, THET

Hero image